Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Drug: Tivozanib for advanced clear cell renal cell carcinoma - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Drug: Tivozanib for advanced clear cell renal cell carcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Tivozanib for advanced clear cell renal cell carcinoma

New Drug: Tivozanib for advanced clear cell renal cell carcinoma
Study:
  • Randomized, open-label phase III trial (TIVO-3)
  • RCC with clear cell component with two or three previous treatments
  • Tivozanib 1.5 mg daily (21/28 days) (n=175) vs. sorafenib 400 mg BID (n=175)
Efficacy:
  • ORR: 18% vs. 8% (all partial, p=0.017)
  • Median DoR: NR vs. 5.7 mos (HR NS)
  • Median PFS: 6.0 vs. 5.4 mos (HR: 0.62 [0.48-0.80])
  • Median OS: 16.4 vs. 19.7 mos (HR NS)
Safety:
  • Grade >=3 AEs: hypertension (20% vs. 14%), diarrhea (2% vs. 10%), PPE (1% vs. 10%), hypothyroidism (1% vs. 0), rash (0 vs. 8%)

Lancet Oncol 2020; 21: 95–104

Rini BI, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

https://doi.org/10.1016/S1470-2045(19)30735-1

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More